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day for 3 days) was started. Blood culture was negative
for any pathogens. Serologic tests for autoimmune
diseases and fungal antigen tests as well as viruses, in-
cluding echovirus, coxsackie virus, and human immu-
nodeficiency virus (HIV), were all negative. Serologic
tests for toxoplasmosis only indicated past infection.
Similarly, quantitative polymerase chain reaction
(PCR) in blood for herpes simplex virus (HSV), vari-
cella-zoster virus (VZV), Epstein-Barr virus (EBV),
adenovirus, human herpes virus 6, parvovirus B19,
and hepatitis B and C virus were all negative. On the
contrary, CMV PCR was strongly positive (7000
copy/mL). Thus, consistent with the result of CMV
pp65 antigenemia, CMV was diagnosed as the main
pathogen of fulminant myocarditis. Because adminis-
tration of ganciclovir was started, her general condi-
tion dramatically improved, CMV antigenemia
decreased to negative value after the transient increase
(peak, 365 positive cells in 2 slides), and all of mechan-
ical cardiopulmonary support devices were success-
fully removed at 2 weeks after their initiation
(Figure 1). Five months after transplantation, she re-
mains in complete remission, without evidence of
heart failure or cardiogenic shock.
CMV infection is a major cause of morbidity and
mortality after hematopoietic stem cell transplantation
(HSCT). Although CMV is a common pathogen of
myocarditis in heart transplant recipients [4], there
were few reports on this disease after allogeneic
HSCT. In this case, she developed presumed fulmi-
nant CMV myocarditis after allogeneic BMT, and
was successfully treated with antiviral therapy and
mechanical circulatory support. Fulminant myocardi-
tis is characterized by an acute onset of severe hemody-
namic instability, and has better long-term prognosis
than patients with nonfulminant myocarditis if recog-
nized promptly and successfully managed with appro-
priate supportive care with inotropes or mechanical
circulatory support [3]. Thus, initiation of mechanical
circulatory support should be useful as a bridge to
recovery for the treatment of fulminant myocarditis
even in allogeneic HSCT recipients. Considering the
efficacy of antiviral therapy, CMV myocarditis should
be taken into account when a patient develops a sudden
onset of acute heart failure or cardiogenic shock after
allogeneic BMT.
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In 1997, Daibata et al. [1] highlighted the remark-
able chromosomal integration of human herpesvirus 6
(HHV6) DNA. We identified a unique case of chro-
mosomally integrated HHV6 (CI-HHV6) after
uncomplicated successful unrelated cord blood stem
cell transplantation (CBT).
A 1.8-year-old boy with mucopolysaccharidosis
type I (Hurler phenotype) was referred for CBT and
received a myeloablative (MA) conditioning regimen
(busulfan [Bu] 480 mg/m2, cyclophosphomide [Cy]
200 mg/kg), including serotherapy with thymoglobu-
lin (Genzyme Corporation, Cambridge, MA). Subse-
quently, a total of 1.5  105 CD341 and 2.5  107
nucleated cells/kg of the recipient bodyweight were in-
fused. As graft-versus-host disease (GVHD) prophy-
laxis, cyclosporine A (CsA; dose is based on plasma
Figure 1. (A) HHV6 DNA load and lymphocyte engraftment after
HSCT. (B) FISH signals on a representative metaphase cell with cohy-
bridization of a control probe from 9p (in green) and an HHV6 specific
probe (in red) showing integration of HHV6 at the telomere region of
the long arm of chromosome 9 (arrow).
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day 128 after CBT, with a taper in 14 days) were
administered. Neutrophil engraftment (.0.5$109
cells/L) occurred on day 118, platelet engraftment
was noted on day 128 (.50$109 cells/L), and stable
100% chimerism was achieved.
The recipient was seropositive for HHV6 prior to
CBT. HHV6 DNA load, measured by quantitative
real-time polymerase chain reaction (PCR), in plasma
on days –32,214, and27 were negative, but appeared
positive only a few hours after CB stem cell infusion
(day 0) [2]. HHV6 DNA load increased and remained
highly positive (105 cp/mL) for more than 2.5 years.
Antiviral treatment with valganciclovir (20 mg/kg/
day) was ineffective (Figure 1A). Therefore, we
hypothesized CI- HHV6 transmitted via CBT. In ret-
rospect, CB unit-derived DNA appeared to be highly
HHV6 DNA positive (107 cp/mL). We analyzed
HHV6 positivity in various cell populations (pure
CD41 T cells, CD81 T cells, CD191 B cells, mono-
cytes and natural killer [NK] cells), sorted by fluores-
cein-activated cell sorting, in a stored sample from 6
months after CBT. Remarkably, all populations werehighly positive for HHV6 DNA, whereas latent
HHV6 infection is characterized by HHV6 positivity
in the T cell population only [3]. Hair follicles were
negative for HHV6DNA, indicating that the recipient
is CI-HHV6 negative. Finally, fluorescein in situ
hybridization (FISH) analysis of chromosome prepa-
rations made from phytohemagglutinin-stimulated
peripheral blood cultures was performed as described
[4] and revealed CI-HHV6 on the telomeric site of
the long arm of chromosome 9 (Figure 1B). As this
patient had achieved 100% donor chimerism, this
CI-HHV6 originated from the CB unit. Others have
shown an incidence of asymptomatic CI-HHV6 in
healthy newborns of 0.86%; thus, there is a possible in-
cidence of 0.86% CI-HHV6 in CBTs [5].
The pattern of HHV6 DNA load in plasma can
easily be misinterpreted as HHV6 reactivation or
infection, as previously observed [6-9]. Our case high-
lights the importance of PCR analysis of the CB unit to
distinguish patients with HHV6 reactivation from pa-
tients with CI-HHV6 to prevent administration of un-
necessary toxic antiviral treatment.
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CCR5 Expression on Cells from
HLA-Matched Unrelated
Marrow Donors and
Graft-versus-Host DiseaseGraft-versus-host disease (GVHD) is a common
complication that is caused by donor T cells following
allogeneic hematopoietic cell transplant. Recently, the
functional state of T cells has been characterized by
their chemokine receptor expression pattern [1]. T
cells expressing chemokine receptor CCR5 contributeTable 1. Transplant outcomes of patients receiving unrelated marr
(+/2) or CCR5632 homozygous (2/2) donors.
+/+ (n 5 344) +/2 (n
Grades II-IV 309 (90%) OR 5 1 34 (87%) OR 5 0.77
Grades III-IV 124 (36%) OR 5 1 13 (33%) OR 5 0.89
Skin* 288 (84%) OR 5 1 18 (46%) OR 5 0.89
Liver* 159 (46%) OR 5 1 32 (82%) OR 5 0.65
Gut* 219 (64%) OR 5 1 14 (36%) OR 5 0.82
Chronic† 207 (60%) HR 5 1 19 (49%) HR 5 0.96
Relapse 66 (19%) HR 5 1 9 (23%) HR 5 1.71
Mortality 167 (49%) HR 5 1 24 (62%) HR 5 1.59
OR indicates odds ratio; HR, hazard ratio.
*Organ-specific graft-versus-host disease (GVHD) of any grade (1-IV).
†Clinical extensive chronic GVHD.to the rejection of solid organ allografts [2] and
development of murine GVHD [3-5]. A nonfunctional
mutant allele of CCR5, CCR5D32, is found with 10%
frequency in Caucasians [6,7]. In a study of renal-
transplant survival, patients homozygous for
CCR5D32 had significantly prolonged graft survival
compared to heterozygous or wild-type patients [8].
Here, we retrospectively compared outcomes among
patients receiving marrow grafts from unrelated do-
nors homozygous for CCR5D32 to those from donors
expressing CCR5.
We screened the donor DNA repository at Fred
HutchinsonCancerCenter for theCCR5D32mutation
by a PCR method [9]. Among 1273 donors, 9 were ho-
mozygous forCCR5D32.Recipients of those bonemar-
row (BM) grafts were predominantly cytomegalovirus
(CMV) patients (CMV 5 8; acute myelogenous leuke-
mia [AML] 5 1), and we therefore decided to confine
our study to the CMV patient group. Patients were 18
to 50 years old and transplanted between 1988 and
2000. They received cyclophosphamide (Cy) and frac-
tionated total body irradiation, unmanipulatedmarrow,
and GVHD prophylaxis with cyclosporine (CsA) and
methotrexate (MTX) [9]. A total of 344 CMV patients
had a CCR5 wild-type donor, 39 had a CCR5D32 het-
erozygous donor, and 8 had a CCR5D32 homozygous
donor. Logistic regression model was used to assess
the association between CCR5 genotype and acute
GVHD (aGVHD), and Cox regression was used for
chronicGVHD(cGVHD)and relapse.As shown inTa-
ble 1, there was less GVHD among patients whose do-
nor was CCR5D32 homozygous compared to patients
with a wild-type or heterozygous donor, although
most of the differences are not statistically significant.
The number of patients with a homozygous donor is
small, making it difficult to derive firm conclusions
even where results are suggestive of a true difference.
Moreover, there are several factors that have an impact
onGVHD, relapse, andmortality.With only 8 patients
with a homozygous donor, we made limited adjust-
ments. After controlling for severity of disease (catego-
rized as low [chronic phase] versus intermediate
[accelerated phase or blast crisis in remission] versusow grafts from CCR5 wild-type (+/+), CCR5632 heterozygous
5 39) 2/2 (n 5 8)
(0.28-2.10, P 5 .61) 6 (75%) OR 5 0.34 (0.07-1.75, P 5 .20)
(0.44-1.79, P 5 .74) 1 (13%) OR 5 0.25 (0.03-2.08, P 5 .20)
(0.37-2.11, P 5 .79) 4 (50%) OR 5 0.19 (0.05-0.80, P 5 .02)
(0.33-1.30, P 5 .22) 2 (25%) OR 5 0.39 (0.08-1.95, P 5 .25)
(0.42-1.61, P 5 .57) 5 (63%) OR 5 0.95 (0.22-4.05, P 5 .95)
(0.60-1.53, P 5 .85) 3 (38%) HR 5 0.45 (0.14-1.41, P 5 .17)
(0.85-3.43, P 5 .13) 3 (38%) HR 5 1.80 (0.57-5.71, P 5 .32)
(1.04-2.44, P 5 .03) 4 (50%) HR 5 1.01 (0.37-2.71, P 5 .99)
